Full-Time

Medical Marketing Communications Manager

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

Montreal, QC, Canada

Hybrid

Category
Growth & Marketing (2)
,
Required Skills
Communications
Marketing
Requirements
  • Bachelor’s or graduate degree in a scientific discipline, preferably health sciences.
  • Previous pharmaceutical industry experience in marketing, communications, regulatory, or medical functions.
  • Significant experience generating and/or editing pharmaceutical copy (5-7 years’ or equivalent combination of education, training, and experience).
  • Extensive hands-on experience with PAAB and ASC submissions and Canadian promotional regulations.
  • Demonstrated medical writing expertise, including strong grammatical, editorial, and proofreading skills.
  • Proven ability to interpret and communicate scientific and medical information clearly and concisely.
  • Strong project management skills with the ability to organize and prioritize multiple projects to agreed timelines.
  • Bilingual in English and French (spoken and written).
  • Strong business acumen, ideally with experience in vaccines or a similar market.
  • Demonstrated learning agility and ability to quickly build therapeutic area knowledge.
  • Proven ability to take on leadership roles, influence senior stakeholders, and advocate for change.
Responsibilities
  • Lead the development and execution of integrated marketing campaigns, assets, and tactics in collaboration with agencies, aligned to brand strategy.
  • Provide decision support for commercial assessments, product forecasting, brand planning, data modeling, and scenario analysis.
  • Partner with promotional review committees (PRC) and stakeholders in Medical Affairs, Compliance, Regulatory, and Legal to develop, review, and refine promotional content.
  • Analyze the effectiveness of marketing initiatives and recommend optimizations.
  • Coordinate with internal and external Communications teams to support key data and study announcements and other external communications.
  • Lead field sales training efforts, including development of sales content strategy and materials.
  • Partner with Marketing Operations to manage promotional material inventory, expiry dates, and re-validation/re-orders as needed.
  • Develop tactical communication plans for all customer segments (HCPs, public health/government officials, advocacy groups, and patients).
  • Distill scientific and clinical information into high-quality, accurate pharmaceutical brand copy for diverse formats and channels.
  • Research, write, and revise science-backed content for review by Medical Affairs.
  • Adapt long-form scientific content into short-form assets (email, social, detailing aids, web, and other platforms).
  • Create on-brand ad copy and content for performance marketing and digital campaigns.
  • Use AI tools to accelerate drafting while maintaining rigor, accuracy, and editorial quality.
  • Edit, fact-check, and proofread clinical and patient-focused materials, ensuring consistency with brand positioning and fair balance.
  • Maintain style guides, core claims documents, and ensure all materials meet PAAB/ASC and Canadian promotional guidelines.
  • Prepare complete and accurate reference packages for seamless submission to PAAB/ASC.
  • Support Market Access, public affairs, and advocacy projects through development of presentations, key messages, and supporting assets.
  • Conduct and/or support market research as needed to inform brand and campaign strategies.
  • Monitor the Canadian vaccines market, provincial influenza programs, and competitive landscape, and regularly present insights and recommendations to internal stakeholders.
  • Support internal quarterly and ad hoc meetings with synthesized data, summaries, and recommendations that aid tactical and strategic decision-making.
  • Lead and manage multiple projects within Canada, liaising with Commercial Operations, Medical Affairs, Market Access, and other key functions.
  • Ensure projects are delivered on time, on budget, and in full compliance with Health Canada, IMC, and PAAB/ASC guidelines and codes of conduct.
  • Act as a subject matter expert in your area, providing guidance on promotional standards and best practices.
  • Influence and manage external partners (advertising, CME, PR/GR, and digital agencies) to deliver high-quality work that meets strategic objectives.
  • Contribute to the development of marketing strategy, including promotional activities and key projects, and highlight market changes that may impact performance.
  • Prioritize and manage multiple concurrent projects and competing deadlines.
  • Navigate differing viewpoints and build consensus among cross-functional stakeholders.
  • Anticipate and address logistical and situational challenges that arise mid-project.
  • Apply clinical and logistical understanding of vaccines to respond to customer needs, maximize opportunities, and mitigate risks.
  • Identify and lead innovative initiatives—particularly in digital channels—to reach and engage customers in new ways (e.g., extended flu season, burden-of-disease awareness).
Desired Qualifications
  • Formal training or certification in medical writing (e.g., AMWA, EMWA).
  • Experience in government relations, public relations, and/or advocacy.
  • Familiarity with principles of clinical research and data interpretation.
  • Experience using AI tools for content development.

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Simplify Jobs

Simplify's Take

What believers are saying

  • HEMGENIX gene therapy sustains 37% factor IX levels through four years post-2025 data.
  • KOSTAIVE self-amplifying mRNA COVID vaccine approved by EC February 2025.
  • VarmX $2.2B acquisition option expands bleeding disorder pipeline in 2026.

What critics are saying

  • Seqirus separation triggers $500M charges and 14% revenue loss from Pentagon mandate scrap.
  • Grifols opens 20 plasma centers by 2027, eroding CSL Behring's immunoglobulin share.
  • Novartis Fabhalta displaces CSL Vifor's $1.5B nephrology revenues within 12 months.

What makes CSL unique

  • CSL Behring leads plasma-derived therapies for haemophilia and immunodeficiencies.
  • CSL Seqirus dominates influenza vaccines with global production scale.
  • CSL Vifor specializes in iron deficiency and nephrology treatments post-2022 acquisition.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at CSL who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Company News

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

Stock Titan
Aug 1st, 2025
Automated Logic Acquires Control Solutions Ltd.

Automated Logic – Canada, Ltd. (ALC), part of Carrier Global Corporation, has acquired Control Solutions, Ltd. (CSL), an independent provider of building-automation systems in Coquitlam, British Columbia. This acquisition establishes ALC's first field office in Vancouver, expanding its presence in Western Canada and enhancing its ability to deliver intelligent building solutions in high-growth sectors across British Columbia.

PharmiWeb.com
Apr 14th, 2025
First Patient Treated With Hemgenix® (Etranacogene Dezaparvovec) Gene Therapy For Haemophilia B In Austria

Vienna, Austria – 9 April 2025 - CSL Behring Austria today announced that the first haemophilia B patient in Austria was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Comprehensive Care Center of the University Hospital of Medicine Vienna.HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1“It is a great opportunity for people with hemophilia B to live a symptom-free life for many years,” explains hematologist Univ.-Prof. Priv.-Doz. Dr Cihan Ay from the Medical University of Vienna, University Clinic for Internal Medicine I Clinical Department for Hematology and Hemostaseology."For the community of affected patients and their families, this represents an enormously significant milestone: the ability to treat hemophilia with gene therapy, and the fact that this option is now available in Austria, is something our community has been eagerly anticipating and hoping for over decades," says Thomas Schindl, MA, Chairman of the Austrian Hemophilia Society (ÖHG)."We are proud and grateful to offer haemophilia B patients in Austria a treatment option that has the potential to transform their lives," said Dr Beate Natmessnig, Managing Director of CSL Behring Austria. "This achievement is the result of outstanding regional and national collaboration among all parties involved and is a strong testament to Austria's innovative capabilities."HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022

PharmiWeb.com
Apr 3rd, 2025
Csl Behring And Gkv-Spitzenverband Agree On Reimbursement Price For Hemgenix® – Europe'S First Gene Therapy For Haemophilia B

Marburg, Germany, 2 April 2025 – CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX®. This agreement marks the availability of the first gene therapy approved in Europe for haemophilia B under an innovative, national, success-based reimbursement model, being implemented for the first time in Germany.HEMGENIX® represents significant progress in the treatment of haemophilia B. The aim of this one-time gene therapy is to eliminate the need for regular factor IX infusions, thereby offering patients the possibility of more freedom from prophylaxis and significantly improving their quality of life.1-4 This development not only provides substantial relief for those affected but also has the potential to reduce long-term costs for the healthcare system.‘The performance-based payment model at national level which was agreed with the GKV-Spitzenverband is unique in Germany. It addresses key reimbursement challenges, such as the question of long-term efficacy, which is inherent for any one-time therapy. Reimbursement is linked to treatment success of the individual patient,’ explains Stefan Neudoerfer, CSL Behring's chief negotiator in Germany.Moreover, this reimbursement model reflects the high therapeutic and innovative value of HEMGENIX® and sets new standards for integrating innovative gene therapies into the German healthcare system.‘The agreement on the reimbursement price of HEMGENIX® is a decisive step for the care of people with haemophilia B in Germany. It enables access to a groundbreaking therapy and recognises the long-term medical and economic benefits of gene therapy,’ explains Christian Wieszner, Managing Director of CSL Behring Germany.With this agreement, CSL Behring is underlining its commitment to innovative therapies that sustainably improve the lives of patients